Thursday, July 29, 2010

Thermo Fisher Gets Cool Reception

The movements of stocks immediately after earnings releases can be so visceral and idiosyncratic that sometimes investors are better off ignoring the noise. Such would seem to be the case for life sciences company Thermo Fisher (NYSE: TMO). Although the stock sold off sharply after earnings, the outlook for this company was not all that bad, and Wall Street's overreaction may give patient investors an interesting long-term opportunity.

The Quarter That Was
Thermo Fisher is never going to be confused with the likes of Illumina (Nasdaq: ILMN) or Luminex (Nasdaq: LMNX) - Luminex is a more diversified, slower-growing play on global life sciences technology. To that point, sales rose more than 6% this quarter, with organic growth a bit below 5%. While Thermo was hurt by weakness in the healthcare and biopharma sectors, and difficult year-over-year comps caused by the H1N1 flu outbreak last year, the industrial side of the business did well. (Learn more about the healthcare sector; see Investing In The Healthcare Sector.)

For the complete piece, please go to:
http://stocks.investopedia.com/stock-analysis/2010/Thermo-Fisher-Gets-Cool-Reception-TMO-ILMN-LMNX-TECH-LIFE-BRKR0729.aspx

No comments: